nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['majestec-2', 'mmsm', 'lenalidomide', 'multiple myeloma', 'daratumumab', 'teclistamab', ' lena', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)']
teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of majestec-2, a phase1b, multicohort study
#ash22 #imfash22 #mmsm
Hematology is in my ??. Posts are mine. Mayo Clinic Associate, Asst Prof, BMT RNCC, RN Navigator, emeritus. IMF NLB. MM KOL. Patient educator & advocate.